• Explore /
  • Poster
  • / <span>Therapeutic effect of gedatolisib, a pan-PI3K/mTOR inhibitor, on prostate cancer models with PI3K or PTEN mutational status.</span>

Therapeutic effect of gedatolisib, a pan-PI3K/mTOR inhibitor, on prostate cancer models with PI3K or PTEN mutational status.

Abstract Poster

Authors

null

Adrish Sen

Celcuity, Minneapolis, MN

Adrish Sen , Salmaan A Khan , Ian A. MacNeil , Benjamin E. Rich , Jhomary S Molden , Laura N Davis , Stefano Rossetti , Aaron M Broege , Lance G. Laing

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 149)

DOI

10.1200/JCO.2023.41.6_suppl.149

Abstract #

149

Poster Bd #

E9

Abstract Disclosures

Similar Posters

First Author: Karim Fizazi

First Author: Hope S. Rugo

Poster

2023 ASCO Annual Meeting

Comprehensive characterization of androgen receptor expression in breast cancer.

Comprehensive characterization of androgen receptor expression in breast cancer.

First Author: Priya Jayachandran

First Author: Robert Wesolowski